SLG
ORTX

Stanley-Laman Group’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Stanley-Laman Group’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,828
Closed -$256K – 286
2019
Q2 		$256K Buy
+1,828
New +$321K 0.06% 248

Other funds holding ORTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Stanley-Laman Group's ORTX Position: Q3 2019 in Review

Stanley-Laman Group sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q3 2019, closing a stake of 1,828 shares — an estimated $256K sold.

Stanley-Laman Group first reported a position in ORTX in Q2 2019 and held it in 1 quarter. The position peaked at $256K in Q2 2019. 62 funds tracked by Wall St. Rank hold ORTX as of Q3 2019.

  • Stanley-Laman Group reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 1,828 Orchard Therapeutics plc American Depositary Shares shares in Q3 2019, an estimated $256K.
  • Stanley-Laman Group first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 1 quarter.
  • Stanley-Laman Group's Orchard Therapeutics plc American Depositary Shares position peaked at $256K in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.